• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of April 10

Video

Here are the top 5 biosimilar articles for the week of April 10, 2023.

Hi, I’m Justina Petrullo for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of April 10th, 2023.

Number 5: Celltrion Healthcare shared data from a phase 3 clinical trial confirming that its omalizumab biosimilar had comparable safety and efficacy to the reference product (Xolair).

Number 4: In IQVIA’s latest report, neurologists in Europe reported feeling positive about the biosimilars for multiple sclerosis (MS) coming down the pipeline, showing that industry-wide education efforts and experience with biosimilars are working to instill greater confidence in these products.

Number 3: A retrospective study from India found that Razumab, a ranibizumab biosimilar, was safe and effective to use in infant patients with retinopathy of prematurity. This is the first analysis assessing the clinical outcomes associated with the biosimilar in this population.

Number 2: STADA Arzneimittel and Xbrane Biopharma announced the launch of Ximluci, a ranibizumab biosimilar referencing Lucentis approved to treat ophthalmic conditions, across the European Union.

Number 1: The European Union gained another high-concentration adalimumab biosimilar with the approval of Sandoz’ Hyrimoz HCF and the FDA accepted a biologics license application for a trastuzumab biosimilar (HLX02).

To read all of these articles and more, visit centerforbiosimilars.com.

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Recent Videos
Here are the top 5 biosimilar articles for the week of July 21, 2025.
Here are the top 5 biosimilar articles for the week of July 14, 2025.
Here are the top 5 biosimilar articles for the week of July 7, 2025.
Here are the top 5 biosimilar articles for the week of June 30, 2025.
Canavan & O’Dell
Here are the top 5 biosimilar articles for the week of June 23, 2025.
Here are the top 5 biosimilar articles for the week of June 16, 2025.
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health.
Here are the top 5 biosimilar articles for the week of June 9, 2025.
Here are the top 5 biosimilar articles for the week of June 2, 2025.
Related Content
© 2025 MJH Life Sciences

All rights reserved.